EBOS seems to be moving on faster-than-expected from its $4bn...

EBOS seems to be moving on faster-than-expected from its $4bn courtship of Greencross, with talk that it is eyeing Paragon Care.
While small, with just a $113.5m market value, Paragon Care operates in the areas of Specialty Diagnostics, Specialty Devices, Capital and Consumables and Service and Technology under brands such as Designs for Vision, Electro Medical Group, Specialist Medical Supplies and Immulab.
It gets parties taking a look at it from time to time.
Apparently, there’s a large Asian private equity firm also interested in buying the business right now.
However, should there be interest, as suggested, it is likely to be early days, with sources close to the company saysing that it has not received approaches.
EBOS has a major earnings hole to fill in the form of the loss of the Chemist Warehouse contract, responsible for providing $1.1bn annually and 17 per cent of its overall revenue.

Despite its net profit increasing 61 per cent to $15.6m in the year to June, it’s curious Paragon Care’s share price has fallen 44 per cent in the past year, which perhaps makes it the right time to strike for a suitor.
Sources say until now, the group has been yet to prove to the market it can deliver on its mergers and acquisition strategy.
Other groups that have looked at Paragon in the past are Navis Capital when it owned Device Technologies.